(4R)-1-{(2S)-2-cyclohexyl-2-[(3,3-dimethylbutyl)amino]acetyl}-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-vinylcyclopropyl}-4-({2-[2-(isopropylamino)-1,3-thiazol-4-yl]-7-methoxy-quinolin-4-yl}oxy)-L-prolinamide | 1179842-87-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4R)-1-{(2S)-2-cyclohexyl-2-[(3,3-dimethylbutyl)amino]acetyl}-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-vinylcyclopropyl}-4-({2-[2-(isopropylamino)-1,3-thiazol-4-yl]-7-methoxy-quinolin-4-yl}oxy)-L-prolinamide
• 英文别名: (2S,4R)-1-[(2S)-2-cyclohexyl-2-(3,3-dimethylbutylamino)acetyl]-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-4-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxypyrrolidine-2-carboxamide
• CAS: 1179842-87-5
• 化学式: C₄₄H₆₁N₇O₇S₂
• 分子量: 864.143
• InChiKey: RSPBZZUERXACML-KOQIVVSISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  60
• 可旋转键数：
  18
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  218
• 氢给体数：
  4
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以7.5 mg的产率得到(4R)-1-{(2S)-2-cyclohexyl-2-[(3,3-dimethylbutyl)amino]acetyl}-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-vinylcyclopropyl}-4-({2-[2-(isopropylamino)-1,3-thiazol-4-yl]-7-methoxy-quinolin-4-yl}oxy)-L-prolinamide
  参考文献：
  名称：

  Inhibitors of the Hepatitis C Virus NS3 Protease with Basic Amine Functionality at the P3-Amino Acid N-Terminus: Discovery and Optimization of a New Series of P2−P4 Macrocycles

  摘要：

  In a follow-Lip to our recent disclosure of P2-P4 macrocyclic inhibitors of the hepatitis C virus (HCV) NS3 protease (e.g., 1, Chart 1), we report a new but related compound series featuring a basic amine at the N-terminus of the P3-amino acid residue. Replacement of the electroneutral P3-amino acid capping group (which is a feature of almost all tripeptide-like inhibitors of NS3 reported to date) with a basic group is not only tolerated but can result in advantageous cell based potency. Optimization of this new class of P3-amine based inhibitors gave compounds such as 25 and 26 that combine excellent cell based activity with pharmacokinetic properties that are attractive for an antiviral targeting HCV.

  DOI：

  10.1021/jm900372w